These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11469717)

  • 1. Targeting the expression of anti-apoptotic proteins by antisense oligonucleotides.
    Delihas N
    Curr Drug Targets; 2001 Jun; 2(2):167-80. PubMed ID: 11469717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.
    Derenne S; Monia B; Dean NM; Taylor JK; Rapp MJ; Harousseau JL; Bataille R; Amiot M
    Blood; 2002 Jul; 100(1):194-9. PubMed ID: 12070027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotides: from design to therapeutic application.
    Chan JH; Lim S; Wong WS
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):533-40. PubMed ID: 16700890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T7 Peptide-Conjugated Lipid Nanoparticles for Dual Modulation of Bcl-2 and Akt-1 in Lung and Cervical Carcinomas.
    Cheng X; Yu D; Cheng G; Yung BC; Liu Y; Li H; Kang C; Fang X; Tian S; Zhou X; Liu Q; Lee RJ
    Mol Pharm; 2018 Oct; 15(10):4722-4732. PubMed ID: 30138565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
    Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense oligonucleotides for the treatment of dyslipidaemia.
    Visser ME; Witztum JL; Stroes ES; Kastelein JJ
    Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mcl-1 blocks radiation-induced apoptosis and inhibits clonogenic cell death.
    Skvara H; Thallinger C; Wacheck V; Monia BP; Pehamberger H; Jansen B; Selzer E
    Anticancer Res; 2005; 25(4):2697-703. PubMed ID: 16080514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells.
    Nahta R; Yuan LX; Fiterman DJ; Zhang L; Symmans WF; Ueno NT; Esteva FJ
    Mol Cancer Ther; 2006 Jun; 5(6):1593-601. PubMed ID: 16818519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
    Gautschi O; Tschopp S; Olie RA; Leech SH; Simões-Wüst AP; Ziegler A; Baumann B; Odermatt B; Hall J; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 2001 Mar; 93(6):463-71. PubMed ID: 11259472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides.
    Sypniewski D; Bednarek I; Gałka S; Loch T; Błaszczyk D; Sołtysik D
    Acta Pol Pharm; 2013; 70(1):87-97. PubMed ID: 23610963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides.
    Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S
    Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense oligonucleotides for cancer therapy-an overview.
    Stahel RA; Zangemeister-Wittke U
    Lung Cancer; 2003 Aug; 41 Suppl 1():S81-8. PubMed ID: 12867066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical and clinical pharmacology of antisense oligonucleotides.
    Marcusson EG; Yacyshyn BR; Shanahan WR; Dean NM
    Mol Biotechnol; 1999 Aug; 12(1):1-11. PubMed ID: 10554769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion.
    Xie Z; Choong PF; Poon LF; Zhou J; Khng J; Jasinghe VJ; Palaniyandi S; Chen CS
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):949-57. PubMed ID: 18259754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligonucleotides targeting c-fos mRNA inhibit rheumatoid synovial fibroblast proliferation.
    Morita Y; Kashihara N; Yamamura M; Okamoto H; Harada S; Kawashima M; Makino H
    Ann Rheum Dis; 1998 Feb; 57(2):122-4. PubMed ID: 9613344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide.
    Olie RA; Hall J; Natt F; Stahel RA; Zangemeister-Wittke U
    Biochim Biophys Acta; 2002 Jun; 1576(1-2):101-9. PubMed ID: 12031489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-cell-membrane-camouflaged supramolecular self-assembly of antisense oligonucleotide and chemodrug for targeted combination therapy.
    Chen T; Xu J; Zhu L; Yan D
    Nanoscale; 2023 Jan; 15(4):1914-1924. PubMed ID: 36617999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consequences of the inhibition of Hdm2 expression in human osteosarcoma cells using antisense oligonucleotides.
    Geiger T; Hüsken D; Weiler J; Natt F; Woods-Cook KA; Hall J; Fabbro D
    Anticancer Drug Des; 2000 Dec; 15(6):423-30. PubMed ID: 11716435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense oligonucleotides: the state of the art.
    Aboul-Fadl T
    Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.